Last year's weakness is ultimately an improved entry opportunity for long-term-minded investors.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

While everyone is discussing are we in an AI bubble or not, Harvard is teaching how to invest in these irrational times.

Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...

Theorem raises $6 million to use AI-powered formal verification to mathematically prove AI-generated code is safe before it's ...

Knowing how to talk to AI" is no longer enough. To stay relevant, developers and workers must master the systematic ...

You are about to hear a lot more about Claude Code.